Intracellular CXCR4+ cell targeting with T22-empowered protein-only nanoparticles

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 4533-4544

  Unzueta, Ugutz ^a,b   Céspedes, María Virtudes ^b,c   Ferrer Miralles, Neus ^a,b   Casanova, Isolda ^b,c   Cedano, Juan ^d   Corchero, José Luis ^a,b   Domingo Espín, Joan ^a,b   Villaverde, Antonio ^a,b   Mangues, Ramón ^b,c   Vázquez, Esther ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

Colorectal cancer; CXCR4; Intracellular targeting; Nanoparticles; Peptide tag; Self assembling

Indexed keywords

CELL PROTEIN; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; GREEN FLUORESCENT PROTEIN; NANOPARTICLE; SYNTHETIC PEPTIDE; T22 PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; COLORECTAL CANCER; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; LYMPH NODE METASTASIS; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PARTICLE SIZE; PERITONEUM METASTASIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN STABILITY; PROTEIN TARGETING; REACTION TIME; TARGET CELL; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; INTRACELLULAR SPACE; MICE; MICROSCOPY, FLUORESCENCE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NANOPARTICLES; PEPTIDES; RECEPTORS, CXCR4; RECOMBINANT FUSION PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS; MEROSTOMATA;

EID: 84866155256     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S34450     Document Type: Article

References (48)

1. Pautler M, Brenner S. Nanomedicine: promises and challenges for the future of public health. Int J Nanomedicine. 2010;5:803-809.
2. Ferrer-Miralles N, Vazquez E, Villaverde A. Membrane-active peptides for non-viral gene therapy: making the safest easier. Trends Biotechnol. 2008;26:267-275.
3. Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov Today. March 23, 2012. [Epub ahead of print.]
4. Peled A, Wald O, Burger J. Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs. 2012;21:341-353.
5. Wilen CB, Tilton JC, Doms RW. Molecular mechanisms of HIV entry. Adv Exp Med Biol. 2012;726:223-242.
6. Klonisch T, Wiechec E, Hombach-Klonisch S, etal. Cancer stem cell markers in common cancers-therapeutic implications. Trends Mol Med. 2008;14:450-460.
7. Sun X, Cheng G, Hao M, etal. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 2010;29:709-722.
8. Kim J, Mori T, Chen SL, etal. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg. 2006;244:113-120.
9. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005;65:967-971.
10. Liang X. CXCR4, inhibitors and mechanisms of action. Chem Biol Drug Des. 2008;72:97-110.
11. Murakami T, Zhang TY, Koyanagi Y, etal. Inhibitory mechanism of the CXCR4 antagonist t22 against human immunodeficiency virus type 1 infection. J Virol. 1999;73:7489-7496.
12. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
13. Vazquez E, Roldan M, Díez-Gil C, etal. Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide. Nanomedicine (Lond). 2010;5:259-268.
14. Vazquez E, Cubarsi R, Unzueta U, etal. Internalization and kinetics of nuclear migration of protein-only, arginine-rich nanoparticles. Biomaterials. 2010;31:9333-9339.
15. Seras-Franzoso J, Díez-Gil C, Vazquez E, etal. Bioadhesiveness and efficient mechanotransduction stimuli synergistically provided by bacterial inclusion bodies as scaffolds for tissue engineering. Nanomedicine (Lond). 2012;7:79-93.
16. Barbera VM, Martin M, Marinoso L, etal. The 18q21 region in colorectal and pancreatic cancer: independent loss of DCC and DPC4 expression. Biochim Biophys Acta. 2000;1502:283-296.
17. Baig MS, Manickam N. Homology modeling and docking studies of Comamonas testosteroni B-356 biphenyl-2,3-dioxygenase involved in degradation of polychlorinated biphenyls. Int J Biol Macromol. 2010; 46:47-53.
18. Cespedes MV, Espina C, Garcia-Cabezas MA, etal. Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol. 2007;170: 1077-1085.
19. Amara A, Gall SL, Schwartz O, etal. HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med. 1997;186:139-146.
20. Zhou NM, Luo ZW, Luo JS, Hall JW, Huang ZW. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II. Biochemistry. 2000;39:3782-3787.
21. Fujii N, Nakashima H, Tamamura H. The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin Investig Drugs. 2003;12:185-195.
22. Ferrer-Miralles N, Corchero JL, Kumar P, etal. Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine. Microb Cell Fact. 2011;10:101.
23. Kucia M, Jankowski K, Reca R, etal. CXCR4-SDF-1signalling, locomotion, chemotaxis and adhesion. J Mol Histol. 2004;35: 233-245.
24. Toledo-Rubio V, Vazquez E, Platas G, etal. Protein aggregation and soluble aggregate formation screened by a fast microdialysis assay. J Biomol Screen. 2010;15:453-457.
25. Domingo-Espin J, Vazquez E, Ganz J, etal. The nanoparticulate architecture of protein-based artificial viruses is supported by protein-DNA interactions. Nanomedicine (Lond). 2011;6:1047-1061.
26. Vazquez E, Corchero JL, Villaverde A. Post-production protein stability:trouble beyond the cell factory. Microb Cell Fact. 2011;10:60.
27. Martinez-Alonso M, Gonzalez-Montalban N, Garcia-Fruitos E, Villaverde A. The functional quality of soluble recombinant polypeptides produced in Escherichia coli is defined by a wide conformational spectrum. Appl Environ Microbiol. 2008;101:1353-1358.
28. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine-challenge and perspectives. Angew Chem Int Ed Engl. 2009;48:872-897.
29. Dietz GP, Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci. 2004;27:85-131.
30. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm. 2011;8:2101-2141.
31. Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci. 2008;29:57-61.
32. Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res. 2009;15: 7471-7478.
33. Jain M, Venkatraman G, Batra SK. Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Clin Cancer Res. 2007;13:1374-1382.
34. Laakkonen P, Vuorinen K. Homing peptides as targeted delivery vehicles. Integr Biol (Camb). 2010;2:326-337.
35. Enback J, Laakkonen P. Tumour-homing peptides: tools for targeting, imaging and destruction. Biochem Soc Trans. 2007;35:780-783.
36. Mocellin S, Lise M, Nitti D. Targeted therapy for colorectal cancer: mapping the way. Trends Mol Med. 2005;11:327-335.
37. Rusconi S, Scozzafava A, Mastrolorenzo A, Supuran CT. An update in the development of HIV entry inhibitors. Curr Top Med Chem. 2007;7:1273-1289.
38. Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Annu Rev Med. 2009;60:207-219.
39. Egorova A, Kiselev A, Hakli M, Ruponen M, Baranov V, Urtti A. Chemokine-derived peptides as carriers for gene delivery to CXCR4 expressing cells. J Gene Med. 2009;11:772-781.
40. Sleeman J, Steeg PS. Cancer metastasis as a therapeutic target. Eur J Cancer. 2010;46:1177-1180.
41. Skipper HE, Schabel FM Jr, Mellett LB, etal. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep. 1970;54:431-450.
42. Villaverde A. Nanotechnology, bionanotechnology and microbial cell factories. Microb Cell Fact. 2010;9:53.
43. Vazquez E, Villaverde A. Engineering building blocks for self-assembling protein nanoparticles. Microb Cell Fact. 2010;9:101.
44. Sadatmousavi P, Soltani M, Nazarian R, Jafari M, Chen P. Self-assembling peptides: potential role in tumor targeting. Curr Pharm Biotechnol. 2011;12:1089-1100.
45. Zhao Y, Tanaka M, Kinoshita T, Higuchi M, Tan T. Self-assembling peptide nanofiber scaffolds for controlled release governed by gelator design and guest size. J Control Release. 2010;147:392-399.
46. Kyle S, Aggeli A, Ingham E, McPherson MJ. Recombinant self-assembling peptides as biomaterials for tissue engineering. Biomaterials. 2010;31:9395-9405.
47. Huang H, Sun XS. Rational design of responsive self-assembling peptides from native protein sequences (dagger). Biomacromolecules. 2010;11:3390-3394.
48. Wu W, Xing L, Zhou B, Lin Z. Active protein aggregates induced by terminally attached self-assembling peptide ELK16in Escherichia coli. Microb Cell Fact. 2011;10:9.